QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors

NCT06892925 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Tumors

Interventions

DRUG: QL1706

Sponsor

Eastern Hepatobiliary Surgery Hospital